US Biologic OrisBio Oral-Delivery Platform
OrisBio US Biologic Oral Delivery Platform

Delivering Disease Prevention®

Orally delivered animal solutions to benefit humans and the environment

Different Species – Different Routes – Different Vaccines

Product development at US BIOLOGIC begins with an animal target species and disease model. Our scientists determine the antigens most likely to be effective against the target diseases, and we examine closely the gut and digestive path of the target animal. Each animal species is different, as is its feeding habits, its environments, and its biome.

US Biologic OrisBio oral delivery platform targeting diseases in mice

Field Mouse

  • Wild-bred
  • Can carry multiple pathogens
  • Outdoors
  • Large numbers
  • Multiple environments
  • Uncontrolled eating habits
  • Single-stomach digestive track
US Biologic OrisBio oral delivery platform targeting canine diseases


  • Wild-bred or pure-breed
  • Indoor or outdoors
  • Multiple sizes / breeds
  • Large numbers
  • Controlled or uncontrolled eating habits
  • Strong preferences for certain foods
  • Single-stomach digestive track
US Biologic OrisBio oral delivery platform targeting poultry diseases


  • Controlled breeding
  • Food animal
  • Multiple stocks and lifespans (breeder, broiler, layer)
  • Large numbers
  • Special feed / water requirements (focus on nutrition)
  • Single stomach with crop digestive track
US Biologic OrisBio oral delivery platform targeting livestock diseases


  • Controlled breeding
  • Multiple breeds / sizes
  • Food animal (meat and milk)
  • Long lifespan
  • Special feed / water requirements (focus on nutrition)
  • Multi-stomached digestive track

Substrate Components

  • Allows integration of diverse and species-specific substrates on which vaccines / therapeutics / additives may be incorporated as an amalgam or as a spray-on.
  • Enables targeted gut placement while maintaining integrity in harsh GI environments.
  • Features the use of coarse textures, providing mechanical stimulation of the animal’s innate immune system.
  • Includes Kibble (smaller animal); Chewable treats (large and small animals); Hard chews (e.g., chew bone); Effervescent tablets (for water system application); and Powders (water or feed application).
US Biologic OrisBio oral delivery platform media
US Biologic pellets - oral delivery media
US Biologic gummies - oral delivery media
US Biologic animal treats - oral delivery media

Bacterial Expression Vehicle Component

  • Vehicle inactivation (downstream process, maintains whole-cell, non-GMO, USDA-supported, increased shelf-life).
  • Recombinant antigen expression system – AVOIDS use of sub-disease or attenuated infectious agents
  • Molecular adjuvantization (cost reduction / no chemical complications).
  • Features:
    • Gut-microbiome friendly (i.e., prebiotic and probiotic) bacterial vehicles
    • Supports complementary antigens, prodrugs, etc.
    • Allows active ingredient inclusion
General Example - Bacterial Vehicle and Protein
US Biologic OrisBio oral delivery platform

Chemical Encapsulation Component

  • Matrix features encapsulation, allowing flexibility in addressing variant levels of gut pH.
  • Matrix serves as a prebiotic.
  • Matrix application is high-throughput, low-cost, and resistant to heat.
  • Matrix, along with inactivation, allows extended shelf-life.

Manufacturing Features

  • Avoids energy-intensive expense of lyophilization.
  • Low-cost capital equipment build / compact design.
  • Allows distributed manufacturing centers.
  • Modular equipment design: Allows coating of a variety of pellet substrates or powdered variants.
  • High throughput pellet-coating:
  • Large quantity of doses with maintained batch consistency.
  • Combined with stabilized inactivation, avoids many challenges associated with cold-chain transport.
US Biologic OrisBio oral delivery platform Global Translation Program


Wickramasuriya SW, Park I, Lee Y, et al. Oral Delivery of Bacillus subtilis Expressing Chicken NK-2 Peptide Protects Against Eimeria acervulina Infection in Broiler Chickens. Front. Vet. Sci., 04 June 2021. doi: 0.3389/fvets.2021.684818

van Oosterwijk JG. Anti-tick and pathogen transmission blocking vaccines. Parasite Immunol. 2021 Mar 11:e12831. doi: 10.1111/pim.12831.

Williams SC, van Oosterwijk JG, Linske MA, et al. Administration of an Orally Delivered Substrate Targeting a Mammalian Zoonotic Pathogen Reservoir Population: Novel Application and Biomarker AnalysisVector Borne Zoonotic Dis. 2020 Mar 26. doi: 10.1089/vbz.2019.2612.

Stafford KC 3rd, Williams SC, van Oosterwijk JG, et al. Field evaluation of a novel oral reservoir-targeted vaccine against Borrelia burgdorferi utilizing an inactivated whole-cell bacterial antigen expression vehicle. Exp Appl Acarol. 2020 Feb;80(2):257-268. doi: 10.1007/s10493-019-00458-1.

Gomes-Solecki M, Arnaboldi PM, Backenson PB, et al. Protective Immunity and New Vaccines for Lyme Disease.
Clin Infect Dis
. 2019 Oct 17. pii: ciz872. doi: 10.1093/cid/ciz872.

Zatechka S. Reservoir-Targeted Vaccines as a One Health Path to Prevent Zoonotic Disease. Int J Vaccines and Vaccination. 2016;6(2). doi: 10.15406/ijvv.2016.02.00049.

Gomes-Solecki M. Blocking pathogen transmission at the source: reservoir targeted OspA-based vaccines against Borrelia burgdorferiFront Cell Infect Microbiol. 2014;4:136. doi: 10.3389/fcimb.2014.00136.

Meirelles Richer L, Brisson D, Melo R, et al. Reservoir Targeted Vaccine Against Borrelia burgdorferi: A New Strategy to Prevent Lyme Disease TransmissionJ Infect Dis. 2014 Jun 15;209(12):1972-80. doi: 10.1093/infdis/jiu005.

Meirelles Richer L, Aroso M, et al. Reservoir targeted vaccine for Lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed miceClin Vaccine Immunol. 2011 Nov;18(11):1809-16. doi: 10.1128/CVI.05226-11.

Gomes-Solecki MJ, Brisson DR, Dattwyler RJ. Oral vaccine that breaks the transmission cycle of the Lyme disease spirochete can be delivered via baitVaccine. 2006 May 15;24(20):4440-9. doi: 10.1016/j.vaccine.2005.08.089.

Intellectual Properties

  • Oral Vaccine for Borrelia; 2005 US
  • Composition & Method for Reducing Zoonotic Infectious Disease; 2015 CA, CN, EP; 2016 US
  • Method for Reducing Zoonotic Infectious Disease (pending; divisional of Composition & Method for Reducing Zoonotic Infectious Disease)
  • Time Release Application and Monitoring System; 2017 CA, CN, EPUS
  • Oral E. coli Vector-Based Vaccine for Prevention of Coccidiosis in Poultry; 2017  CN, US
  • A Viral-Vectored Composition and Method of Use (pending)
  • Composition and Method of an Orally Administered Antimicrobial Peptide Vectored in a Bacterial Expression Vehicle (pending)